Description
5-Amino-1MQ 50mg Pen is listed by Peptide Pro for controlled in-vitro laboratory and analytical . The 50mg presentation forms part of the Peptide Pro UK catalogue.
In scientific and analytical literature, 5-Amino-1MQ is described as a small-molecule NNMT inhibitor compound rather than a peptide. Recognised terminology includes 5-amino-1-methylquinolinium. commonly relates to NNMT-related enzyme, metabolic-pathway and small-molecule .
The 50mg identifies this catalogue presentation. Any analytical documentation displayed on this page applies only to the named tested sample and batch/reference shown. Results from another strength, batch or compound must not be treated as evidence for this product.
5-Amino-1MQ context and terminology
5-Amino-1MQ is described in scientific and analytical literature as a small-molecule NNMT inhibitor compound rather than a peptide. Recognised terminology includes 5-amino-1-methylquinolinium. Common terms include NNMT inhibitor, quinolinium compound, small molecule. These terms identify the subject and should not be read as product-specific analytical evidence.
5-Amino-1MQ 50mg specifications and evidence
Current product specifications, price, availability, storage information and the current product image remain in the existing product panel above. Where analytical documentation is available, read it only in relation to the exact sample, batch/reference and result shown on that report. A report for another strength, batch or compound must not be presented as evidence for this product.
5-Amino-1MQ sources and internal links
For broader scientific background, use the 5-Amino-1MQ profile and established literature databases where relevant. Useful internal routes: Peptide Pro testing and batch verification, verify the official Peptide Pro website, and 5-Amino-1MQ 50mg.
Related records
Related records include AICAR 50mg, NAD+ 1000mg and MOTS-C 40mg. Use Peptide Pro Quality & Testing and Official Website Verification to confirm the current site, documentation policy and available product-specific evidence.
